TMPRSS2-ERG-mediated feed-forward regulation of wild-type ERG in human prostate cancers

Ram-Shankar Mani1, Matthew K Iyer, Qi Cao

  • 1Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA.

Cancer Research
|June 17, 2011
PubMed

Insights

The TMPRSS2-ERG gene fusion drives overexpression of wild-type ERG in prostate cancer. This overexpression is linked to increased cancer invasiveness, offering new insights into ERG regulation.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Recurrent ETS gene fusions are hallmarks of prostate cancer, with TMPRSS2-ERG being the most prevalent.
  • While TMPRSS2-ERG fusion transcripts are understood, the regulation of wild-type ERG in prostate cancer remains unclear.

Purpose of the Study:

  • To investigate the regulatory mechanisms of wild-type ERG expression in prostate cancer.
  • To determine the functional and clinical significance of wild-type ERG overexpression driven by TMPRSS2-ERG fusions.

Main Methods:

  • Integrative analysis of gene expression and genomic data.
  • Gene knockdown and overexpression studies in prostate cancer cell lines (VCaP and PC3).
  • Analysis of wild-type ERG expression in clinical prostate cancer samples.

Main Results:

  • The TMPRSS2-ERG fusion protein binds to the ERG locus, driving wild-type ERG overexpression.
  • Knockdown of TMPRSS2-ERG reduced wild-type ERG transcription, while its overexpression increased it.
  • Androgen signaling modulates TMPRSS2-ERG, consequently upregulating wild-type ERG.
  • Loss of wild-type ERG expression correlated with reduced cellular invasion.
  • Overexpression of wild-type ERG was observed in 38% of localized and 27% of metastatic prostate cancers with TMPRSS2-ERG fusions.

Conclusions:

  • The TMPRSS2-ERG fusion is a key driver of wild-type ERG overexpression in prostate cancer.
  • Wild-type ERG overexpression, regulated by TMPRSS2-ERG and androgen signaling, may contribute to prostate cancer progression and invasiveness.
  • These findings elucidate a novel regulatory pathway for ERG in prostate cancer.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Master Transcription Regulators02:23

Master Transcription Regulators

Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a  complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
The Unfolded Protein Response01:37

The Unfolded Protein Response

The ER is the hub of protein synthesis in a cell. It has robust systems to quality control protein folding and also for degradation of terminally misfolded proteins. Under normal conditions, a small proportion of misfolded proteins that cannot be salvaged need to be transported to the cytoplasm by the ER-associated degradation or ERAD pathways. However, if the ERAD cannot handle the misfolded proteins, the cell activates the unfolded protein response or UPR to adjust the protein folding...